Grant: Canada Postdoctoral Research Award (CPRA) program
Université Laval
$140,000.00
Airway microbiome as a novel therapeutic target for pulmonary hypertension
EF 2025-26
Résumé
Pulmonary hypertension (PH) is a serious condition caused by high blood pressure in the lungs. It can lead to heart failure and death, and current treatments are not always effective. New strategies are urgently needed.
Recent research suggests that certain bacteria in the mouth may help the body produce nitric oxide, a substance that widens blood vessels and may ease PH symptoms. In people with PH, we found fewer of these helpful bacteria, and this was linked to more severe disease.
We believe that changing the bacteria in the airways could offer a new way to treat PH. This project has 2 main aims:
1. Computer Modeling: We will use data from PH patients around the world to map how bacteria in the airways change in upper vs lower airway, and characterise over time at different stages of the disease. We will focus on identifying key bacteria that may help produce nitric oxide.
2. Animal Testing: In lab models of PH, we will test whether increasing helpful bacteria or reducing harmful ones can improve symptoms. We'll also study how long these changes last.
Perspectives: If successful, this work will lay the foundation for the first human trial to test if changing airway bacteria is safe in healthy people.
Backed by experts in PH and airway microbiome research, this project could lead to a completely new and innovative treatment option for patients living with PH.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537893
Name
Yang Haopu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Airway microbiome as a novel therapeutic target for pulmonary hypertension
Programtype2
Fellowship Programs
Orgnameinp2
Université Laval
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Airway Microbiome; Microbiome Engineering; Pulmonary Hypertension
Abstract
Pulmonary hypertension (PH) is a serious condition caused by high blood pressure in the lungs. It can lead to heart failure and death, and current treatments are not always effective. New strategies are urgently needed.
Recent research suggests that certain bacteria in the mouth may help the body produce nitric oxide, a substance that widens blood vessels and may ease PH symptoms. In people with PH, we found fewer of these helpful bacteria, and this was linked to more severe disease.
We believe that changing the bacteria in the airways could offer a new way to treat PH. This project has 2 main aims:
1. Computer Modeling: We will use data from PH patients around the world to map how bacteria in the airways change in upper vs lower airway, and characterise over time at different stages of the disease. We will focus on identifying key bacteria that may help produce nitric oxide.
2. Animal Testing: In lab models of PH, we will test whether increasing helpful bacteria or reducing harmful ones can improve symptoms. We'll also study how long these changes last.
Perspectives: If successful, this work will lay the foundation for the first human trial to test if changing airway bacteria is safe in healthy people.
Backed by experts in PH and airway microbiome research, this project could lead to a completely new and innovative treatment option for patients living with PH.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Yang, Haopu
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~